Orally Active Benzamide Antipsychotic Agents with Affinity for Dopamine D2, Serotonin 5-HT1A, and Adrenergic α1Receptors
Citations Over TimeTop 15% of 1998 papers
Abstract
New antipsychotic drugs are needed because current therapy is ineffective for many schizophrenics and because treatment is often accompanied by extrapyramidal symptoms and dyskinesias. This paper describes the design, synthesis, and evaluation of a series of related (aminomethyl)benzamides in assays predictive of antipsychotic activity in humans. These compounds had notable affinity for dopamine D2, serotonin 5-HT1A, and alpha1-adrenergic receptors. The arylpiperazine 1-[3-[[4-[2-(1-methylethoxy)phenyl]-1-piperazinyl]methyl]benzoyl]p ipe ridine (mazapertine, 6) was chosen because of its overall profile for evaluation in human clinical trials. The corresponding 4-arylpiperidine derivative 67 was also highly active indicating that the aniline nitrogen of 6 is not required for activity. Other particularly active structures include homopiperidine amide 14 and N-methylcyclohexylamide 31.
Related Papers
- → Mechanisms of action of atypical antipsychotic drugs(1991)253 cited
- → The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: A pet study(1995)233 cited
- → The Importance of Serotonin-Dopamine Interactions in the Action of Clozapine(1992)136 cited
- → The Design and Synthesis of a Hapten for 1192U90, a Potential Atypical Antipsychotic Agent(1996)1 cited
- Perospirone,a novel atypical antipsychotic drug(2006)